Anavex Life Sciences

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Anavex Life Sciences reports Q1 results, highlights precision medicine focus

Anavex Life Sciences showcased positive results in the Alzheimer's study and emphasized precision medicine in addressing neurological disorders.
The company's financial performance, with a net loss of $13 million and a cash position of $143.6 million, reflects ongoing research and development efforts.
Challenges include financial losses, regulatory discussions, and operational complexities, while opportunities lie in upcoming data readouts and new clinical trials.
Overall, Anavex's strategic focus on precision medicine and diverse pipeline position it for potential growth and advancements in neurological treatments.

Anavex Life Sciences reports Q2 results, eyes pipeline expansion

Anavex Life Sciences reported a mixed financial performance in Q2 2023 but maintains a strong cash position for future operations and clinical programs.
The company's focus on Alzheimer's disease treatments, pipeline expansion, and team strengthening reflect a commitment to advancing innovative therapies.
While facing financial challenges and competitive pressures, Anavex has opportunities to leverage its clinical successes, new hires, and partnerships for future growth.

Anavex Life Sciences reports Q3 loss, eyes neurology breakthroughs

Anavex Life Sciences is actively pursuing clinical advancements in neurology with a focus on blarcamesine. Despite financial challenges, the company's strategic partnerships and pipeline expansion position it well for future growth and innovation.

Anavex Life Sciences reports strong cash position amidst strategic focus

Anavex Life Sciences demonstrated financial strength with a substantial cash position in Q4 2023, while facing challenges with a net loss.
The company's strategic focus on precision medicine programs and ongoing trials presents opportunities for growth and innovation in the healthcare sector.
Navigating regulatory processes and balancing financial sustainability will be key for Anavex to capitalize on its strengths and address operational challenges.

Anavex Life Sciences reports Q1 loss but advances precision medicine

Anavex Life Sciences reported financials reflecting a net loss but with a solid cash position, emphasizing fiscal responsibility and ongoing research progress.
The company's strengths lie in its financial stability, innovative precision medicine focus, and commitment to addressing neurological disorders.
Challenges include managing financial losses, meeting regulatory timelines, and balancing fiscal prudence with research investments.
Opportunities arise from upcoming submissions, precision medicine trends, therapeutic expansion, and potential collaborations.

Anavex Life Sciences reports Q2 progress amidst analyst inquiries

Anavex Life Sciences is actively pursuing the development of therapies for various neurological disorders. The company faces challenges in FDA guidance interpretation, European filings, and commercialization strategies. However, with a solid cash position and a focus on transformative therapies, Anavex has significant growth opportunities.

Anavex Life Sciences reports Q3 results, advances precision medicine

Anavex Life Sciences showcased financial stability with a strong cash position despite reporting a net loss, underlining their commitment to advancing treatments for brain disorders.
Progress in trials for blarcamesine in Alzheimer's disease and other neurological conditions signals potential breakthroughs in precision medicine.
While facing challenges such as managing losses and regulatory uncertainties, Anavex remains poised to leverage opportunities through upcoming data releases and regulatory submissions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Health Canada Special Access Program (SAP) Authorizes ANAVEX®2-73 (blarcamesine) for patients after successful completion of Open-Label Extension (OLE) study

ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome

NEW YORK, June 12, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced the publication of a relevant new peer-reviewed study in the American Journal on Intellectual and Developmental Disabilities, entitled ‘Rett Syndrome Behaviour Questionnaire in Children and Adults With Rett Syndrome: Psychometric Characterization and Revised Factor Structure'. 1

Anavex Life Sciences Reports Publication in Medical Journal Signifying Continued Commitment for Improvement of the Rett Syndrome Caregiver Outcome Measure RSBQ

Here is how Anavex Life Sciences (AVXL) and Clene Inc. (CLNN) have performed compared to their sector so far this year.

Is Anavex Life Sciences (AVXL) Outperforming Other Medical Stocks This Year?

Blarcamesine, a sigma-1 receptor agonist, may be a more effective antioxidant than Aricept and galantamine in treating Alzheimer's disease. If granted accelerated approval by the FDA, Anavex's stock value is expected to rise significantly. Anavex may provide the best investment opportunity and drug hope for the near long-term stabilization of mild Alzheimer's disease in those with functioning sigma-1 receptors.

Anavex's Blarcamesine: Sigma-1 Receptor Agonists And Antioxidants For Alzheimer's Disease

NEW YORK, June 06, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced the completion of dosing of all participants of the placebo-controlled EXCELLENCE Phase 2/3 study ANAVEX®2-73-RS-003 in pediatric patients with Rett syndrome. The Company expects to announce topline results from this study in the second half of this year.

Anavex Life Sciences Announces Completion of ANAVEX(®)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, announced today it was awarded new U.S. Patent No. 11,661,405 entitled “CRYSTAL FORMS OF TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3-FURANMETHANAMINE HYDROCHLORIDE, PROCESSES OF MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS” from the United States Patent and Trademark Office (USPTO), expanding Anavex's patent coverage of certain crystal forms of ANAVEX®2-73 (blarcamesine) compositions, processes of preparation, and uses thereof.

ANAVEX Announces Issuance of New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73 (blarcamesine)

The average of price targets set by Wall Street analysts indicates a potential upside of 338.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Anavex Life Sciences (AVXL) Could Surge 338.45%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 342.3% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 342.31%: Here's is How to Trade

Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q2 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Clint Tomlinson - Investor Relations Christopher Missling - President and Chief Executive Officer Sandra Boenisch - Principal Financial Officer Conference Call Participants Soumit Roy - Jones Research Clint Tomlinson Good morning. Welcome to the Anavex Life Sciences Fiscal 2023 Second Quarter Conference Call.

Anavex Life Sciences Corp. (AVXL) Q2 2023 Earnings Call Transcript

Newly available preliminary efficacy results of surrogate biomarkers from the ANAVEX®2-73-AD-004 study; allowing initiation of discussions with regulatory agencies for Accelerated Approval Pathway for ANAVEX®2-73 (blarcamesine) in Alzheimer's disease with convenient oral treatment

Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results

Webcast and Conference Call To be Held Tuesday, May 9, 2023, 8:30 am ET Webcast and Conference Call To be Held Tuesday, May 9, 2023, 8:30 am ET

Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023

NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, announced today it was granted a new U.S. Patent No. 11,622,955 entitled “SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY,” from the United States Patent and Trademark Office (USPTO), expanding Anavex's coverage of treatment methods for ANAVEX®2-73 (blarcamesine), to the treatment of systolic hypertension, or lowering systolic blood pressure.

Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension

NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference at NASDAQ being held May 2nd, 2023 at 9:30am ET at NASDAQ World Headquarters New York City.

Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other Central Nervous System (CNS) diseases, today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the 22nd Annual Needham Virtual Healthcare Conference 2023 on Monday, April 17, 2023, at 8:00 AM ET.

Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023

Study successfully achieved both primary and secondary objectives

ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson's Disease Dementia

The ANAVEX2-73-AD-004 trial was mostly positive. A reputable journal article on the missing data would allay fears of a 'spin'.

Buy Anavex For Its Likely Positive Alzheimer's Disease Data

The number of people with dementia is expected to rise significantly, and that presents a big opportunity. Anavex 2-73 shows potential as a treatment for Alzheimer's, Parkinson's, dementia, and other indications.

Wall Street Thinks This Small-Cap Stock Can Quadruple in Value

Anavex seems to have effectively handled the Rett syndrome endpoint issues. A future publication should also throw more light on the AD data.

Anavex: Many Questions Answered, A Few Still Left, But Things Are Progressing Well

Anavex is a clinical-stage biotech stock with no revenue. The company's lead therapy is being tested to treat a host of neurodegenerative and neurological conditions.

Why Shares of Anavex Life Sciences Rose 12.4% in February

A short squeeze could be a possibility if the company can prove that bearish investors are wrong about its business.

Is Anavex Life Sciences Stock a Buy Now?

The mean of analysts' price targets for Anavex Life Sciences (AVXL) points to a 270.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Anavex Life Sciences (AVXL) Have the Potential to Rally 270.28% as Wall Street Analysts Expect?

Short-sellers have piled into this clinical-stage biopharma stock.

This Short-Squeeze Candidate Could Actually Pan Out in the Long Run

Anavex Life Sciences recently reported their Q1 2023 earnings that revealed a beat on EPS and a robust cash position that should fund the company for the next four years. The company updated investors on ANAVEX 2-73 in Alzheimer's and publicized that they “plan to submit the data for publication and peer-reviewed medical journal in the near term”.

Anavex Life Sciences: Recent Earnings Reveals Strong Cash Position To Get ANAVEX 2-73 Through FDA

The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results.

Why Anavex Life Sciences Stock Bolted Higher in January

Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q1 2023 Earnings Conference Call February 7, 2023 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants Soumit Roy - Jones Trading Yun Zhong - BTIG Clint Tomlinson Good morning, everyone. And welcome to the Anavex Life Sciences' Fiscal 2023 First Quarter Conference Call.

News for Anavex Life Sciences Stock (AVXL)